熊出没之夺宝熊兵

闽商走进昌吉木垒开展产销对接_我的网站

上锁的房间

一 | Shares of Pfizer are in retreat on the first day of trading after the drug company said sales of its COVID-19 vaccine and its coronavirus treatment are weaker than it had expected and cut revenue projections by $9 billion for the year. Falling sales of both clipped sales in the second quarter, but Pfizer said in August that it expected a rebound in the second half of 2023. Shares of Pfizer slipped more than 1% before the opening bell Monday and Moderna, which is heavily reliant on the competing vaccine it makes, slid nearly 5%. Pfizer said Friday that global usage of Paxlovid is trending slightly above last year, but that it's still below expectations.The fall vaccination period just began and the New York City drugmaker said that it's too soon to get a handle on vaccination rates for the year.Full-year revenue for Paxlovid and Comirnaty is expected to be approximately $12.5 billion, short $9 billion of what it had expected. Pfizer is lowering its full-year revenue expectations for Paxlovid by approximately $7 billion. That number also accounts for delayed commercialization of the product, which was pushed to January 2024 from the company's previous expectation of commercialization in the second half of this year. Pfizer is also lowering its 2023 revenue expectations for Comirnaty by approximately $2 billion due to lower-than-expected vaccination rates.Pfizer Inc. now foresees 2023 revenue in a range of $58 billion to $61 billion, down from its prior forecast for $67 billion to $70 billion. It now projects full-year adjusted earnings between $1.45 and $1.65 per share due to lower-than-anticipated revenue for COVID-19-related products and inventory write-offs.That is short of the full-year revenue of $63.61 billion and earnings of $2.77 per share that Wall Street was expecting, and far short of the company's previous projections of per-share earning between $3.25 and $3.45. JPMorgan said the company's update solves an ongoing U.S. Paxlovid inventory debate and it anticipates the company's bigger-than-expected cuts to its sales projections will help put a floor under per-share earnings expectations for next year.。 AI摘要漳州援疆牵线，木垒县与厦门漳州商会签订牛羊肉购销协议，打通销往福建通道。双方还在新能源、文旅等领域挖掘合作机遇，推动产业援疆由单向帮扶转向双向赋能。东南网8月21日讯（福建日报报业集团记者陈小清通讯员陈细慧） 8月19日，在2026年闽商昌吉行启动仪式暨木垒县招商推介会上，新疆昌吉州木垒县农畜龙头企业与厦门市漳州商会成功牵手，双方签订牛羊肉购销意向协议，当地特色农畜产品打通销往福建沿海的通道。此次产销对接由福建援疆漳州分指挥部牵线搭桥。为促成本次合作，来自福建的企业家代表团赴木垒开展实地考察，走访了当地肉制品加工、鹰嘴豆深加工、新能源装备制造等多家企业，调研农牧业、新能源、文旅产业发展现状，并走进福建援疆漳州分指挥部，感受漳木两地跨越山海的情谊。据悉，依托龙头企业带动，木垒已构建集饲草种植、良种繁育、屠宰加工、冷链物流等于一体的完整肉羊产业集群，推行“一标、一号、一码”溯源体系，保障农畜产品品质可追溯。此次协议达成后，木垒羊肉将借助商会渠道直达福建各地，实现牧场到餐桌的直达。推介会上，木垒县全面展示资源禀赋。作为古丝绸之路重要驿站，木垒不仅风光电规划装机容量超8000万千瓦，是重要新能源基地，还拥有“中国鹰嘴豆之乡”“中国长眉驼之乡”称号，羊肉、鹰嘴豆等国家地理标志产品极具市场竞争力，吸引企业家高度关注，各方有意在农副产品深加工、新能源、文旅康养领域挖掘合作机遇。本次活动收获多项务实成果。除牛羊肉购销意向协议外，长眉驼乳业、美之羡肉制品、鹰哥生物3家本土企业还向厦门市漳州商会授予产品代理权限，助力木垒特产向外拓展。厦门市漳州商会会长曾建华表示，将发挥平台优势，推广木垒农特产品，带动更多闽商来木垒投资兴业。自对口支援木垒以来，漳州产业援疆由单向帮扶转向双向赋能，近3年组织本地企业参加展销活动20余场，订单总额超6000万元，在漳州落地15家新疆特产门店。